Dr. Stephen Henry Wrzesinski, MD, PhD

  • Albany, NY
  • Medical oncologist
NPI1780856971PAC ID7113105958
Medicare services, 2024
34,684
Medicare patients, 2024
411
Part D claims, 2024
783
Publications
9
Clinical trials
2
Practice address
400 Patroon Creek Blvd, Albany, NY 12206
Practice phone
Call (518) 239-5200
Professional email
Get professional email
Personal email
Get personal email
Mobile number
Get mobile number
Social profiles

Primary practice

Akira Medical Imaging + Wellness

Mammography / Breast Imaging Center · Albany, New York

See all 9 affiliations

Find Dr. Wrzesinski's professional email, personal email and mobile number

Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.

View contacts for free

Dr. Stephen Henry Wrzesinski is a medical oncologist in Albany, New York

Dr. Wrzesinski practices at Akira Medical Imaging + Wellness in Albany, New York.

Dr. Wrzesinski's NPI, 1780856971, was assigned on March 27, 2008. Dr. Wrzesinski graduated from State University of NY Upstate Medical University in 2002. Dr. Wrzesinski holds New York license 260820.

NPI and contact details
Medicare PAC ID
7113105958
NPI enumeration date
March 27, 2008
NPI status
Active
Accepts Medicare assignment
Yes
Offers telehealth
Yes
Practice phone
(518) 239-5200
Professional email
Get email
Personal email
Get email
Mobile number
Get number
Sex
Male
Estimated age
50
Medical school graduation
2002

Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)

Dr. Stephen Henry Wrzesinski practices at Akira Medical Imaging + Wellness in Albany, New York

Dr. Wrzesinski's primary practice is Akira Medical Imaging + Wellness, at 400 Patroon Creek Blvd, Albany, NY 12206. The practice phone is (518) 239-5200.

  • Akira Medical Imaging + Wellness
    400 Patroon Creek Blvd, Albany, NY 12206Phone(518) 239-5200

Source: Dmand AI Affiliation Data

Dr. Stephen Henry Wrzesinski is affiliated with 7 sites of care and 2 medical groups

Dr. Wrzesinski's primary practice is Akira Medical Imaging + Wellness in Albany, New York. Dr. Wrzesinski is also affiliated with Albany Medical Center. The medical group on file is Samaritan Hospital. Dmand AI also links Dr. Wrzesinski to 4 more hospitals, 1 hospice and 1 medical group, each named with a free account. Dr. Wrzesinski's employer is on file too: a breast imaging center.

See all 9 affiliations for Dr. Wrzesinski

Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data

Dmand AI tracks the EHR system at Dr. Stephen Henry Wrzesinski's practice

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wrzesinski practices, 7 sites in all. Vendor and product names are available with a free account.

EHR by site
SiteEHR vendor and product
Akira Medical Imaging + WellnessAvailable with a free account
+6 more sites and 1 medical groupAvailable with a free account

Source: Dmand AI Technology Install Data

For health IT teams

See the EHR and IT leaders at every site where Dr. Wrzesinski practices

Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.

Dr. Stephen Henry Wrzesinski is one of 458 medical oncologists in New York

Medical oncology is Dr. Wrzesinski's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Wrzesinski is licensed in New York.

Specialties and state licenses

  • Medical oncology, New YorkPrimaryLicense 260820 · taxonomy 207RX0202X

Medical oncologists near Dr. Wrzesinski

Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.

458medical oncologists in New York
7medical oncologists in Albany

Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks

Dr. Stephen Henry Wrzesinski billed Medicare for 34,684 services in 2024

CMS data shows 34,684 Medicare services from Dr. Wrzesinski across 54 procedure codes in 2024, for 411 Medicare patients. Medicare paid $940,668 for them.

Medicare services, 202434,684
Medicare patients411
Paid by Medicare$940,668
Procedure codes54

Dr. Wrzesinski's Medicare services by type, 2023 to 2024

  • 2023
  • 2024
Drugs given in the office
2023: 41,4302024: 26,43936%
Other services
2023: 2,5402024: 3,47237%
Lab and pathology
2023: 2,1192024: 2,38813%
Tests and treatments
2023: 8562024: 8944%
Office and hospital visits
2023: 7772024: 7612%
Surgery
2023: 6002024: 6315%
Imaging
2023: 812024: 9922%

Where Dr. Wrzesinski's Medicare services took place, 2024

  • In an office34,615100%
  • In a facility690%

Dr. Wrzesinski compared with the New York median for medical oncologists, 2024

  • Dr. Wrzesinski
  • New York median
Medicare services
34,684vs 340102.0 times
Medicare patients
411vs 1123.7 times
Part D claims
509vs 1303.9 times

Medians across 421 medical oncologists in New York with Dmand AI profiles that report each measure.

Dr. Wrzesinski's most billed Medicare procedure codes, 2024

CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.

See all procedures by Dr. Wrzesinski

Need commercial claims for Dr. Wrzesinski?

Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Wrzesinski and other medical oncologists in New York.

Book a meeting

Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks

Dr. Stephen Henry Wrzesinski treated 411 Medicare patients in 2024, average age 74

CMS counts 411 Medicare patients who saw Dr. Wrzesinski in 2024. The largest group is 65 to 74, with 175 patients. 73% of them have high blood pressure, and 71% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Wrzesinski's median patient age at 70, with 47% women.

Medicare patients, 2024411
Average age74
Average risk score2.36
Also on Medicaid13%

Dr. Wrzesinski's Medicare patients by age, 2024

Dr. Wrzesinski's Medicare patients by sex, 2024

  • Women19848%
  • Men21352%

Chronic conditions among Dr. Wrzesinski's Medicare patients, 2024

  1. High blood pressure73%
  2. High cholesterol71%
  3. Cancer66%
  4. Arthritis37%
  5. Anxiety33%
  6. Ischemic heart disease32%
  7. Diabetes27%
  8. Mood disorders25%

Share of Medicare patients with each condition. A patient can have several.

Dr. Wrzesinski's patients across all payers

Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.

Patient panel by age, all payers

Median age 70

Patient panel by sex, all payers

  • Women47%
  • Men52%

Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data

Dr. Stephen Henry Wrzesinski wrote 783 Medicare Part D claims in 2024

In 2024, Dr. Wrzesinski wrote 783 Medicare Part D claims for 108 patients. 76% of them were for generic drugs. CMS names the drug for 509 of them, across 21 drugs with 11 or more claims each, at $909,269 in total drug cost. In 2023, CMS named 632 claims across 24 drugs.

Part D claims, 2024783
Drugs named by CMS21
Total drug cost$909,269
Part D patients108

Dr. Wrzesinski's Part D claims by kind of drug, 2024

  • Generic595 claims76%
  • Brand-name188 claims24%

Dr. Wrzesinski's most prescribed drugs by claims, 2024

CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.

Drug classes CMS tracks in Dr. Wrzesinski's Part D claims, 2024

  • Opioids4%28 of 783 claims
  • Antibiotics3%20 of 783 claims
  • Antipsychotics, patients 65 and over2%15 of 783 claims

Share of all Part D claims for each drug class CMS reports on. Classes with no claims are left out.

Part D claims for drugs CMS names, 2023 to 2024

  • 2023
  • 2024
Claims for drugs CMS names
2023: 6322024: 50919%

Drugs named by CMS: 21 in 2024, 24 in 2023.

See all prescribing by Dr. Wrzesinski

Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data

Dr. Stephen Henry Wrzesinski offers telehealth to Medicare patients

Dr. Wrzesinski accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Wrzesinski as offering telehealth.

Accepts Medicare assignment
Yes
Offers telehealth
Yes

Source: Doctors and Clinicians National Downloadable File (CMS)

For MedTech and pharma teams

Find medical oncologists like Dr. Wrzesinski by procedure volume and prescribing

Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.

Dr. Stephen Henry Wrzesinski has 9 publications on record

Dmand AI links 9 papers to Dr. Wrzesinski, published from 2010 to 2022. 2010 was the busiest year, with 2. The most frequent topics are Antineoplastic Agents. Dr. Wrzesinski's most frequent co-authors are Atu Agawu, MD, MPH, Zainub Ajmal, MD and Marc Stuart Ernstoff, MD.

Papers9
Years published2010 to 2022

Dr. Wrzesinski's papers by year, 2010 to 2022

Topics Dr. Wrzesinski writes about most

  • Antineoplastic Agents

Dr. Wrzesinski's most frequent co-authors

Recent publications by Dr. Wrzesinski

See all 9 publications and co-authors

See who Dr. Wrzesinski researches with

Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Wrzesinski works with, so you can find a warm path to the right medical oncologists.

How network discovery works

Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage

Dr. Stephen Henry Wrzesinski has worked on 2 clinical trials

Dmand AI links Dr. Wrzesinski to 2 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Melanoma, Squamous Cell Carcinoma of Head and Neck and Carcinoma, Squamous Cell.

Conditions in Dr. Wrzesinski's trials

  • Melanoma
  • Squamous Cell Carcinoma of Head and Neck
  • Carcinoma, Squamous Cell
  • Nevi and Melanomas

Investigators on the most trials with Dr. Wrzesinski

Recent clinical trials with Dr. Wrzesinski

Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)

Dr. Stephen Henry Wrzesinski received $6,650 in industry payments from 2016 to 2025

CMS Open Payments shows 27 general payments to Dr. Wrzesinski from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. Amgen Inc. paid the most, $2,399.

General payments to Dr. Wrzesinski by program year, 2016 to 2025

General payments to Dr. Wrzesinski by kind, 2016 to 2025

$6.7Kin total
  • Consulting fees$5,16878%
  • Food and beverage$1,25319%
  • Education$2303%

Companies that paid Dr. Wrzesinski the most, 2016 to 2025

Share is of all general payments to this clinician.

See all payments to Dr. Wrzesinski

Source: Open Payments (CMS), 2025 data, released July 7, 2026

Dr. Stephen Henry Wrzesinski graduated from State University of NY Upstate Medical University

Dr. Wrzesinski graduated from State University of NY Upstate Medical University in 2002.

  1. Medical schoolState University of NY Upstate Medical University

Source: Dmand AI Professional Profile Data

Sources for Dr. Stephen Henry Wrzesinski's profile data

Sources for the data on this page
Data on this pageSource
NPI, name, sex, specialty and licensesNPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data
Practice locations and phoneDmand AI Affiliation Data
Primary practice, affiliations and health systemDmand AI Affiliation DataDmand AI Org Hierarchy Data
Medicare services and procedure codesMedicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab)
State medians for the same specialtyDmand AI Peer Benchmarks
Medicare patients and the all-payer patient panelDmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab)
Part D prescribingMedicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab)
MIPS scores, telehealth, assignment and procedure percentilesDoctors and Clinicians National Downloadable File (CMS) (opens in a new tab)
Publications, topics and co-authorsPubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage
Clinical trials and co-investigatorsDmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab)
Industry paymentsOpen Payments (CMS) (opens in a new tab)
Training, board certification and membershipsDmand AI Professional Profile Data
EHR at each practice siteDmand AI Technology Install Data
Similar physiciansDmand AI Affiliation Data

Data last refreshed October 2026Report an inaccuracyRemove my information

FAQ

Frequently asked questions about Dr. Stephen Henry Wrzesinski

Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.

What is Dr. Stephen Henry Wrzesinski's NPI number?

Dr. Stephen Henry Wrzesinski's NPI number is 1780856971. It was assigned on March 27, 2008, and it is active in the NPI Registry.

What kind of doctor is Dr. Stephen Henry Wrzesinski?

Dr. Stephen Henry Wrzesinski is a medical oncologist in Albany, New York. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).

Where does Dr. Stephen Henry Wrzesinski practice?

Dr. Wrzesinski practices at 400 Patroon Creek Blvd, Albany, NY 12206. Dr. Wrzesinski's primary practice is Akira Medical Imaging + Wellness in Albany, New York. Dmand AI also links Dr. Wrzesinski to 4 hospitals, 1 hospice and 1 medical group.

What is Dr. Stephen Henry Wrzesinski's office phone number?

The practice phone on file for Dr. Wrzesinski is (518) 239-5200.

What is Dr. Stephen Henry Wrzesinski's medical license number?

Dr. Wrzesinski holds New York license 260820.

Which hospitals is Dr. Stephen Henry Wrzesinski affiliated with?

Dr. Wrzesinski is affiliated with Albany Medical Center. Dmand AI links Dr. Wrzesinski to 4 more hospitals.

What medical group is Dr. Stephen Henry Wrzesinski part of?

Dr. Wrzesinski is linked to Samaritan Hospital. Dmand AI links Dr. Wrzesinski to 1 more medical group.

Does Dr. Stephen Henry Wrzesinski accept Medicare?

Yes. CMS data shows Dr. Wrzesinski billed Medicare for 34,684 services in 2024, and Dr. Wrzesinski accepts Medicare assignment.

Does Dr. Stephen Henry Wrzesinski offer telehealth?

Yes. The CMS Doctors and Clinicians file lists Dr. Wrzesinski as offering telehealth services.

How many Medicare patients does Dr. Stephen Henry Wrzesinski see?

CMS counts 411 Medicare patients who saw Dr. Wrzesinski in 2024, with an average age of 74.

Show 7 more questionsShow fewer questions

What services does Dr. Stephen Henry Wrzesinski bill to Medicare?

In 2024, Dr. Wrzesinski's most billed Medicare services were injected or infused drug (J9271), injected or infused drug (J1453) and injected or infused drug (J0897).

Where did Dr. Stephen Henry Wrzesinski go to medical school?

Dr. Wrzesinski graduated from State University of NY Upstate Medical University in 2002.

What drugs does Dr. Stephen Henry Wrzesinski prescribe most?

In 2024 Medicare Part D data, Dr. Wrzesinski's most prescribed drugs by claims were Dexamethasone, Eliquis and Levothyroxine Sodium.

Has Dr. Stephen Henry Wrzesinski received payments from drug or device companies?

CMS Open Payments shows $6,650 in general payments to Dr. Wrzesinski from 12 companies from 2016 to 2025. The largest total came from Amgen Inc.

How long has Dr. Stephen Henry Wrzesinski been practicing?

Dr. Wrzesinski graduated from medical school in 2002, 24 years ago.

Does Dr. Stephen Henry Wrzesinski do research?

Dmand AI links 9 publications to Dr. Wrzesinski, published from 2010 to 2022. Dr. Wrzesinski has worked on 2 clinical trials.

Who does Dr. Stephen Henry Wrzesinski publish with?

Dr. Wrzesinski's most frequent co-authors are Atu Agawu, MD, MPH (1 shared paper), Zainub Ajmal, MD (1 shared paper) and Marc Stuart Ernstoff, MD (1 shared paper).

Selling to medical oncology practices?

See medical oncologists in New York by site of care and group

Find the practices, groups and hospitals they work with, and the right people to contact at each.

  • 30 days free
  • Self-serve
  • No credit card

Cookie settings

Turn each category on or off. Your choice is kept for 12 months and you can change it here at any time.

Necessary

Always on. Sign-in, security, downloads you asked for, your cookie choice, and the page that led to a signup.

View cookies (6)
  • dm_consentDmand AI. Your cookie choices and whether your browser sent a Global Privacy Control signal. 12 months.
  • dm_ft, dm_ltDmand AI. The first and the latest page you arrived on, with the date, so a signup is credited to the page that worked. 90 days, 30 days.
  • dm_fs, dm_lsDmand AI. The first and the latest source of a visit (a search engine, a campaign or the site that linked here). 90 days, 30 days.
  • dm_dl, dm_dl_okDmand AI. After you give an email address for a download, lets you download files without being asked again. 30 days.
  • Session and CSRF cookiesDmand AI (app.dmand.ai). Sign-in and form protection in the application. Session.
  • __cf_bm, cf_clearanceCloudflare. Tells people from automated traffic and keeps the site available. 30 minutes; cf_clearance while a security check is valid.

Analytics

On unless you turn it off. How pages are used, in aggregate, and recordings of how pages are used.

View cookies (6)
  • Google Tag ManagerGoogle. Loads the analytics and marketing tags that are on. Sets no cookie of its own and does not load when both categories are off. n/a.
  • _ga, _ga_<container-id>Google Analytics 4. Visits and page views in aggregate on dmand.ai. 2 years.
  • _clck, _clskMicrosoft Clarity. Recordings and heatmaps of how pages are used, with form fields masked. 1 year, 1 day.
  • CLID, MUID, ANONCHK, MR, SMMicrosoft (clarity.ms). Set by Microsoft when Clarity loads, to recognize a browser across sites that use Clarity. Up to 1 year.
  • None (cookieless)Ahrefs Analytics. Page views in aggregate. n/a.
  • ph_<project>_posthogPostHog. Product usage, errors and performance in app.dmand.ai, used to fix bugs and improve features. 365 days.

Marketing

On unless you turn it off, and always off when your browser sends a Global Privacy Control signal. A visitor identification service tells our sales team which companies and people visit.

View cookies (6)
  • _reb2buid, _reb2butkRB2B. Recognizes a returning browser for visitor identification. 360 days, 1 year.
  • _reb2bgeoRB2B. The location used to decide whether a visit can be identified. 20 days.
  • _reb2brefRB2B. The page or site that referred the visit. 15 days.
  • _reb2bfxf, _reb2btd, _reb2bliRB2B. Links the visit to an identified business profile. 1 month.
  • _reb2bresolveRB2B. Holds a match while it is being resolved. 2 days.
  • _reb2sessionID, _reb2bloadedRB2B. The current visit, and a guard against loading the script twice. 30 minutes, 1 second.

Functional

On unless you turn it off. Remembers choices such as a collapsed section.

View cookies (none today)